Lumira Ventures IV final closes at US $220M

Photo of author

By CPE News

CPE News (7/26/2021) – Lumira Capital Investment Management Inc., dba Lumira Ventures, has held final closing for Lumira Ventures IV with total capital commitments of US $220 million.

Lumira Ventures IV Limited Partner (LP) investors include BC Tech Fund/Kensington Capital Partners, Fonds de Solidarité FTQ, Northleaf Capital Partners, Caisse de dépôt et placement du Québec, the Business Development Bank of Canada, Teralys Capital, the Ontario Capital Growth Corporation, Royal Bank of Canada, Investissement Québec, Fondaction, Alexandria Venture Investments, Angelini Pharma, China Grand Pharmaceutical and Healthcare Holdings, Vancity, and Amana Global Partners.

Lumira Ventures IV will be led by General Partners (GPs), Gerlad Brunk, Peter van der Velden, Benjamin Rovinski, and Daniel Hétu.

Lumira Ventures has also closed a US $35 million strategic venture fund in partnership with an unnamed international pharmaceutical company. Lumira previously managed a strategic venture fund committed by Merck & Co., Inc. and supported by Teralys Capital (Merck Lumira Biosciences Fund).

1 – Lumira held an initial close for Lumira Capital IV which later re-sequenced as Lumira Capital III then renamed again as Lumira Ventures III.
2 – Angelini Lumira Biosciences Fund (ALBF) is the US $35 million strategic fund managed on behalf Angelini Pharma which is the sole institutional investor. Angelini Pharma also commits US $5 million to Lumira Ventures IV. Angelini Pharma is an international pharmaceutical company, part of the Italian privately-owned Angelini Group.

photo credit: Bill Oxford on Unsplash